ACAD
32.081
+0.421
+1.3282%
AEMD
5.698
+0.098
+1.7571%
APRI
0.389
+0.02
+5.3900%
ARNA
1.74
+0.03
+1.75%
ATEC
0.347
+0.026
+8.201%
CNAT
2.05
+0.02
+0.99%
CRXM
0.101
-0.059
-36.717%
CYTX
2.063
+0.033
+1.6010%
DXCM
79.69
+1.65
+2.11%
GNMK
8.415
+0.135
+1.630%
HALO
8.33
+0.16
+1.96%
ILMN
137.165
+2.155
+1.596%
INNV
0.218
-0.002
-1.0455%
INO
9.17
-0.04
-0.43%
ISCO
2.03
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
121.26
+3.62
+3.08%
LPTN
2.218
+0.168
+8.195%
MBVX
0.548
-0.016
-2.9083%
MEIP
1.33
-0.04
-2.92%
MNOV
7.21
-0.08
-1.10%
MRTX
5.39
-0.18
-3.23%
MSTX
0.475
+0.003
+0.636%
NBIX
44.91
+1.03
+2.35%
NUVA
59.68
+0.91
+1.55%
ONCS
1.7
+0.02
+1.19%
ONVO
3.69
+0.33
+9.82%
OREX
0.443
+0.013
+3.0691%
OTIC
15.68
0.00
0.00%
QDEL
17.575
+0.075
+0.429%
RCPT
231.96
0.00
0.00%
RGLS
2.71
+0.17
+6.69%
RMD
61.8
+1.46
+2.42%
SCIE
0.004
0.00
-2.2727%
SPHS
2.19
+0.18
+8.9652%
SRNE
5.8
+0.06
+1.05%
TROV
4.56
+0.03
+0.66%
VICL
4.51
+0.12
+2.73%
VOLC
18
0.00
0.00%
ZGNX
8.07
+0.18
+2.28%
ACAD
32.081
+0.421
+1.3282%
AEMD
5.698
+0.098
+1.7571%
APRI
0.389
+0.02
+5.3900%
ARNA
1.74
+0.03
+1.75%
ATEC
0.347
+0.026
+8.201%
CNAT
2.05
+0.02
+0.99%
CRXM
0.101
-0.059
-36.717%
CYTX
2.063
+0.033
+1.6010%
DXCM
79.69
+1.65
+2.11%
GNMK
8.415
+0.135
+1.630%
HALO
8.33
+0.16
+1.96%
ILMN
137.165
+2.155
+1.596%
INNV
0.218
-0.002
-1.0455%
INO
9.17
-0.04
-0.43%
ISCO
2.03
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
121.26
+3.62
+3.08%
LPTN
2.218
+0.168
+8.195%
MBVX
0.548
-0.016
-2.9083%
MEIP
1.33
-0.04
-2.92%
MNOV
7.21
-0.08
-1.10%
MRTX
5.39
-0.18
-3.23%
MSTX
0.475
+0.003
+0.636%
NBIX
44.91
+1.03
+2.35%
NUVA
59.68
+0.91
+1.55%
ONCS
1.7
+0.02
+1.19%
ONVO
3.69
+0.33
+9.82%
OREX
0.443
+0.013
+3.0691%
OTIC
15.68
0.00
0.00%
QDEL
17.575
+0.075
+0.429%
RCPT
231.96
0.00
0.00%
RGLS
2.71
+0.17
+6.69%
RMD
61.8
+1.46
+2.42%
SCIE
0.004
0.00
-2.2727%
SPHS
2.19
+0.18
+8.9652%
SRNE
5.8
+0.06
+1.05%
TROV
4.56
+0.03
+0.66%
VICL
4.51
+0.12
+2.73%
VOLC
18
0.00
0.00%
ZGNX
8.07
+0.18
+2.28%
Home » Archive by Category

Xconomy

Making the Price Right: Ideas To Change Drug Costs Gain Momentum

April 5, 2016 – 5:45 am

If the U.S. presidential primaries continue their current trajectories, the two contenders come autumn will have at least one thing in common: a stated desire to do something about high drug prices….

[[Click headline to continue reading.]]

$220M Richer, Human Longevity Ups Ante In Genomics Business Race

April 4, 2016 – 4:56 pm

Human Longevity, the private San Diego startup aiming to turn DNA from tens of thousands of people into a range of new businesses, said this afternoon it has reeled in $220 million in venture cash….

[[Click headline to continue reading.]]

Napa Summit 2016: Request Your Invite to Our Most Special Event

April 4, 2016 – 6:46 am

There are all sorts of reasons for requesting an invitation to Xconomy’s Napa Summit, which will take place in just six weeks—on May 16-17.  One is the fantastic array of speakers: John Maeda,…

[[Click headline to continue reading.]]

When Data Meets Genomics, Where Does Computing Power Come From?

April 1, 2016 – 8:09 am

San Antonio—Even as genome sequencing has risen in prevalence and declined in cost during the last decade, it still has many scientists perplexed from a data standpoint. As it becomes more…

[[Click headline to continue reading.]]

What’s Ahead for Biotech in 2016: Q&A With BIO Chair Ron Cohen

March 31, 2016 – 6:55 am

Biotechnology is a tricky business. We all know the trials and tribulations—and costs—of bringing novel drugs to market. In the past six months or so, a new round of drug pricing upheaval…

[[Click headline to continue reading.]]

New PureTech Startup Commense Aims to Protect Babies From Disease

March 31, 2016 – 5:50 am

[Updated, 12:15 pm ET, see below] Boston company creator PureTech Health already has one microbiome startup in its portfolio, Vedanta Biosciences. Today it’s unveiled a second one, Commense, with a…

[[Click headline to continue reading.]]

The Xconversation: Vaccine Developer Meets Energy Innovator, Part II

March 30, 2016 – 3:20 am

There’s no such thing as failure, as long as you view it in the proper light. That’s the philosophy of scientist-entrepreneurs Darrick Carter, vice president of adjuvant technology at…

[[Click headline to continue reading.]]

The Xconversation: Vaccine Developer Meets Energy Innovator, Part I

March 29, 2016 – 3:20 am

What do vaccines have to do with batteries? Let your mind’s eye travel to the cellular membrane, where a ligand is enveloped by a receptor, spurring a subtle change in the cell. (Bear with me.)…

[[Click headline to continue reading.]]

West Coast Bio Roundup: Gilead, Affymetrix, Acutus, Frazier & More

March 25, 2016 – 7:13 am

Gilead Sciences is back at the top of our chart for the second week in a row. After halting trials last week in the United States and Europe over its cancer drug idelalisib, a federal jury in San…

[[Click headline to continue reading.]]

CRISPR And Beyond: UCSD-Doudna Work Attracts Paul Allen’s Millions

March 23, 2016 – 2:33 pm

CRISPR-Cas9 is well known, by people who follow science and some who don’t, as the new DNA editing tool that one day might cure genetic diseases or lead to designer babies. Or both. Whether…

[[Click headline to continue reading.]]